Localised forms of pulmonary amyloidosis

Česká verzia

Authors: Eva Mnacakanová ¹; Lenka Henzlová ²; MUDr. Pavla Flodrová, Ph.D. ³; Tomáš Pika ¹
Authors place of work: Hemato-onkologická klinika Lékařské fakulty Univerzity Palackého v Olomouci a Fakultní nemocnice Olomouc ¹; Klinika nukleární medicíny Lékařské fakulty Univerzity Palackého v Olomouci a Fakultní nemocnice Olomouc ²; Ústav klinické a molekulární patologie Lékařské fakulty Univerzity Palackého v Olomouci ³
Published in the journal: Vnitř Lék 2021; 67(6): 357-364
Category: Case reports

Summary

Amyloidosis is a rare disorder caused by amyloid deposits in various organs and tissues resulting in vital organ dysfunction, eventually death. There are two forms of amyloidosis – systemic, characterized by multiple organs affected, and localized (focal). Localized forms of amyloidosis usually affect urinary bladder, skin and lungs. Pulmonary amyloidosis may be localized or systemic such as diffuse alveolo-septal pulmonary amyloidosis which usually accompanies systemic AL amyloidosis. Other two forms of pulmonary amyloidosis are tracheobronchial and nodular. All three forms are usually detected by accident when patients undergo chest examination for different reasons as most cases of pulmonary amyloidosis are asymptomatic. The prognosis of localized amyloidosis is good with 5-year overall survival being 90,6 %. In our case report we present three patients diagnosed with localized pulmonary amyloidosis at our center. In all cases the diagnoses were made following the resection of affected lung segments with no further treatment needed.

Keywords:

Amyloidosis – alveolo-septal amyloidosis – localized amyloidosis – nodular pulmonary amyloidosis – tracheobronchial amyloidosis

Zdroje

1. Kufová Z, Pika T, Jelínek T et al. Hereditární amyloidózy – etiologie, klinický obraz a léčba. Transfuze Hematol. dnes. 2015; 21(4): 184–192.

2. Ryšavá R. Systémové amyloidózy a jejich léčba. Maxdorf: Praha 2013. ISBN 978–80– 7345–341–1.

3. Benson MD, Buxbaum JN, Eisenberg DS et al. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2020; 27(4): 217–222.

4. Pika T, Hájek R et al. Diagnostika a léčba systémové AL amyloidózy: Doporučení vypracovaná Českou myelomovou skupinou (CMG) a Myelomovou sekcí České hematologické společnosti ČLS JEP. Transfuze Hematol. dnes. 2019; 25(Supplementum 1): 35–70.

5. Quock TP, Yan T, Chang E et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018; 2(10): 1046–1053.

6. Mahmood S, Sachchithanantham S, Bridoux F et al. Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years. Blood. 2013; 122 (21): 3143.

7. Krishnan J, Chu WS, Elrod JP et al. Tumoral presentation of amyloidosis (amyloidomas) in soft tissue. A report of 14 cases. Am J Clin Pathol. 1993;100(2):135–44.

8. Buadi F. Localized Amyloidosis. In: MA, Gertz a Rajkumar SV. Amyloidosis: Diagnosis and Treatment. Humana Press. 2010, s. 95–106. ISBN 978–1-61779–692–0.

9. Basset M, Hummedah K, Kimmich C et al. Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression. Am J Hematol. 2020; 95: 1158– 1169.

10. Lesser A. Ein Fall von Enchondroma osteiodes mixtum der Lunge mit partieller amyloid Entotung. Virchows Arch (Pathol Anat) 1877; 69: 404–408.

11. Clark JM, Weissler MC. Localized tracheobronchial amyloidosis: case report and review of the literature. Ear Nose Throat J. 2001; 80: 635–636.

12. Chung MJ, Lee KS, Franquet T. et al. Metabolic lung disease: imaging and histopathologic findings. Eur J Radiol. 2005; 54(2): 233–45.

13. Brandelik SC, Heussel CP, Kauczor HU et al. CT features in amyloidosis of the respiratory system – Comprehensive analysis in a tertiary referral center cohort. Eur J Radiol. 2020; 129: 109123.

14. Marchiori E, Escuissato DL, Souza AS Jr et al. Computed tomography findings in patients with tracheal paracoccidioidomycosis. J Comput Assist Tomogr. 2008; 32(5): 788–91.

15. Marchiori E, Pozes AS, Souza AS Jr et al. Diffuse abnormalities of the trachea: computed tomography findings. J Bras Pneumol. 2008; 34: 47–54.

16. Milani P, Basset M, Russo F et al. The lung in amyloidosis. Eur Respir Rev. 2017; 26(145): 170046.

17. Moore A., Kramer MR, Silvern D et al. Endobronchial brachytherapy-A novel approach for the management of airway amyloidosis. Brachytherapy. 2018 Nov-Dec;17(6): 966–972.

18. Neben-Wittich MA, Foote RL, Kalra S. External beam radiation therapy for tracheobronchial amyloidosis. Chest. 2007 Jul;132(1): 262–7.

19. Lim JK, Lacy MQ, Kurtin PJ et al. Pulmonary margine zone lymphoma of MALT type as a cause of localised pulmonary amyloidosis. Journal of Clinical Pathology. 2001; 54: 642–646.

20. Baumgart JV, Stuhlmann-Laeisz C, Hegenbart U et al. Local vs. systemic pulmonary amyloidosis-impact on diagnostics and clinical management. Virchows Arch. 2018; 473(5): 627–637.

21. Clark CM, Schneider JA, Bedell BJ et al. Use of Florbetapir-PET for Imaging β-Amyloid Pathology. JAMA. 2011; 305(3): 275–283.

22. Dorbala S, Vangala D, Semer J et al. Imaging cardiac amyloidosis: a pilot study using ¹⁸F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41(9):1652– 62.

23. Wagner T., Page J., Burniston M et al. Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds. Eur J Nucl Med Mol Imaging. 2018;45(7):1129–1138.

24. Urban BA, Fishman EK, Goldman SM et al. CT evaluation of amyloidosis: spectrum of disease. Radiographics. 1993;13:1295–1308.

25. Kaplan B, Martin BM, Boykov O et al. Co-deposition of amyloidogenic imunoglobulin light and heavy chaos in localized pulmonary amyloidosis. Virchows Arch. 2005;447:754–761.

26. Calatayud J, Candelas G, Gómez A et al. Nodular pulmonary amyloidosis in a patient with rheumatoid arthritis. Clin Rheumatol. 2007; 26(10): 1797–8.

27. Yang MC, Blutreich A, Das K. Nodular pulmonary amyloidosis with an unusual protein composition diagnosed by fine-needle aspiration biopsy: a case report. Diagn Cytopathol. 2009; 37(4): 286–9.

28. Roden AC, Aubry MC, Zhang K et al. Nodular senile pulmonary amyloidosis: a unique case confirmed by immunohistochemistry, mass spectrometry, and genetic study. Hum Pathol. 2010; 41(7): 1040–5.

29. Ikeda SI, Hineno A, Yoshinaga T et al. Sjögren syndrome-related plasma cell disorder and multifocal nodular AL amyloidosis: clinical picture and pathological findings. Amyloid. 2019; 26(4): 225–233.

30. Gillmore JD, Hawkins PN. Amyloidosis and the respiratory tract. Thorax. 1999; 54: 444–451.

31. Howard S, Jagannathan J, Krajewski K et al. Multimodality imaging in amyloidosis. Cancer Imaging. 2012;12:109–117.

32. Marchiori E, Souza AS Jr, Franquet T et al. Diffuse high-attenuation pulmonary abnormalities: a pattern-oriented diagnostic approach on high-resolution CT. Am J Roentgenol. 2005; 184: 273–282.

33. Jeong YJ, Lee KS, Chung MP et al. Amyloidosis and lymphoproliferative disease in Sjögren syndrome: thin-section computed tomography findings and histopathologic comparisons. J Comput Assist Tomogr. 2004; 28: 776–781.

34. Westermark P. Localized AL amyloidosis: a suicidal neoplasm? Ups J Med Sci. 2012; 117(2): 244–50.

35. Adam Z, Elleder M, Moulis M et al. Přínos PET-CT vyšetření pro rozhodování o léčbě lokalizované nodulární formy plicní AL-amyloidózy. Vnitř Lék 2012; 58(3): 241–252.

36. Koukalová R, Szturz P, Svobodová I et al. Ložisková amyloidóza v dutině nosní. Klin Onkol. 2016; 29(3): 216–9.

37. Glaudemans AW, Slart RH, Noordzij W et al. Utility of 18F-FDG PET(/CT) in patients with systemic and localized amyloidosis. Eur J Nucl Med Mol Imaging. 2013 Jul; 40(7): 1095–101.

38. Mekinian A, Jaccard A, Soussan M et al. 18F-FDG PET/CT in patients with amyloid light- chain amyloidosis: case-series and literature review. Amyloid. 2012 Jun;19(2): 94-8.